Alberts Liquid Waste
As Seen On "All for Nothing" Episode #2035 (Oprah Winfrey Network). Albert #39;s Liquid Waste provides Septic Pumping Service, Installations, Repairs and Portabl...
By: johnbarclayca
Read the rest here:
Alberts Liquid Waste - Video
IBLS | L.2 Immunology
King Abdulaziz University Faculty of Medicine Second Year Med12 Module:Immune,Blood and Lymphatic Systems Medical Microbiology and Parasaitology : Lecture 2.
By: Med12KAU
Bref. Nous sommes Technico-Commerciaux en Instrumentation Biotechnologique et Biomédicale!
Présentation de la licence pro TCIBB, réalisée par la promo TCIBB 2012-2013. Pour tout renseignement : caroline.norez@univ-poitiers.fr.
By: Caroline Norez
Go here to read the rest:
Bref. Nous sommes Technico-Commerciaux en Instrumentation Biotechnologique et Biomédicale! - Video
IBLS | L.3 Immunology
King Abdulaziz University Faculty of Medicine Second Year Med12 Module:Immune,Blood and Lymphatic Systems Medical Microbiology and Parasaitology : Lecture 3.
By: Med12KAU
Read the original post:
IBLS | L.3 Immunology - Video
MISSISSAUGA, Ontario, April 8, 2013 /PRNewswire/ --CML HealthCare Inc. (CLC.TO) (the "Company" or "CML"), a leading community-based provider of laboratory and medical imaging services in Ontario and British Columbia, and BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced an agreement for CML to install two BD Kiestra Total Laboratory Automation ("TLA") systems. This fully automated microbiology system will be installed at CML's central laboratory by the third quarter of 2013. The BD Kiestra TLA system is designed to significantly increase overall microbiology lab productivity, streamline workflow, and shorten the time to results.
"We are very excited to be the first laboratory services provider in North America to be installing the BD Kiestra TLA system. With our central laboratory processing approximately three million microbiology tests annually, this installation will be the largest in the world for the BD Kiestra TLA system," said Thomas Wellner, President and CEO of CML. "The implementation of the BD Kiestra TLA system will allow CML to increase our capacity, reduce result turnaround times, and contribute to the growth of our core laboratory business. It will provide us with a significant competitive advantage and support a key pillar of our growth strategy which is to establish innovative hospital and other partnerships."
BD Kiestra TLA system automates the manual processes associated with inoculating and incubating microbiology specimens, and uses digital imaging of the inoculated specimens to shorten the time to detect bacterial growth. The increased efficiency, and quality improvements associated with automation allow for faster delivery of more accurate results to provide optimal patient care. In addition, laboratory staff is able to devote more time to analytical and value-added tasks.
"BD is proud to be working with CML HealthCare Inc., one of Canada's largest and most forward-looking laboratory services providers," said Tom Polen, President, BD Diagnostics - Diagnostic Systems. "Rapid diagnosis and treatment of infections is critical; however, many of the traditional testing protocols take two or three days to generate an actionable result.Using the BD Kiestra TLA system, integrated with other rapid diagnostic technologies, CMLwill be a pioneer in implementing technology that can often reduce those times significantly. We expect this to enable clinicians to provide patients with the most effective treatment earlier thus improving the standard of care and avoiding unnecessary healthcare costs."
The BD Kiestra TLA system currently has an installation base of instruments at public hospitals, universities, and privately owned laboratories in more than eleven countries worldwide since its introduction in 2006.
About CML HealthCare Inc.
Based in Mississauga, Ontario, CML HealthCare Inc. is a leading community-based, medical diagnostic services provider in Canada operating 114 Client C.A.R.E. Centres in Ontario, 84 imaging centres in Ontario and British Columbia, and a reference laboratory in Ontario focused on specialized coagulation testing and equipment calibration for international customers. CML is publicly-traded on the Toronto Stock Exchange under the symbol "CLC" and has approximately 89.8 million common shares outstanding. For more information, please visit http://www.cmlhealthcare.com or follow CML on Twitter @cmlhealthcare.
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.
For more information, please contact:
Read the original here:
CML HealthCare Inc. to Install North America's First and World's Largest Fully Automated BD Kiestraâ„¢ Microbiology ...
MISSISSAUGA, ONTARIO--(Marketwired - Apr 8, 2013) - CML HealthCare Inc. (CLC.TO) (the "Company" or "CML"), a leading community-based provider of laboratory and medical imaging services in Ontario and British Columbia, and BD (Becton, Dickinson and Company) ("BD"), a leading global medical technology company, today announced an agreement for CML to install two BD Kiestra Total Laboratory Automation ("TLA") systems. This fully automated microbiology system will be installed at CML's central laboratory by the third quarter of 2013. The BD Kiestra TLA system is designed to significantly increase overall microbiology lab productivity, streamline workflow, and shorten the time to results.
"We are very excited to be the first laboratory services provider in North America to be installing the BD Kiestra Total Laboratory Automation system. With our central laboratory processing approximately three million microbiology tests annually, this installation will be the largest in the world for the BD Kiestra TLA system," said Thomas Wellner, President and CEO of CML. "The implementation of the BD Kiestra TLA system will allow CML to increase our capacity, reduce result turnaround times, and contribute to the growth of our core laboratory business. It will provide us with a significant competitive advantage and support a key pillar of our growth strategy which is to establish innovative hospital and other partnerships."
BD Kiestra TLA system automates the manual processes associated with inoculating and incubating microbiology specimens, and uses digital imaging of the inoculated specimens to shorten the time to detect bacterial growth. The increased efficiency, and quality improvements associated with automation allow for faster delivery of more accurate results to provide optimal patient care. In addition, laboratory staff is able to devote more time to analytical and value-added tasks.
"BD is proud to be working with CML HealthCare Inc., one of Canada's largest and most forward looking laboratory services provider," said Tom Polen, President BD Diagnostics - Diagnostic Systems. "Rapid diagnosis and treatment of infections is critical; however, many of the traditional testing protocols take two or three days to generate an actionable result. Using the BD Kiestra TLA system, integrated with other rapid diagnostic technologies, CML will be a pioneer in implementing technology that can often reduce those times significantly. We expect this to enable clinicians to provide patients with the most effective treatment earlier - thus improving the standard of care and avoiding unnecessary healthcare costs."
The BD Kiestra TLA System currently has an installation base of instruments at public hospitals, universities, and privately owned laboratories in more than eleven countries worldwide since its introduction in 2006.
About CML HealthCare Inc.
Based in Mississauga, Ontario, CML HealthCare Inc. is a leading community-based, medical diagnostic services provider in Canada operating 114 Client C.A.R.E. Centres in Ontario, 84 imaging centres in Ontario and British Columbia, and a reference laboratory in Ontario focused on specialized coagulation testing and equipment calibration for international customers. CML is publicly-traded on the Toronto Stock Exchange under the symbol "CLC" and has approximately 89.8 million common shares outstanding. For more information, please visit http://www.cmlhealthcare.com or follow CML on Twitter @cmlhealthcare.
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.
Public release date: 9-Apr-2013 [ | E-mail | Share ]
Contact: Jim Sliwa jsliwa@asmusa.org 202-942-9297 American Society for Microbiology
Newly discovered mouse viruses could pave the way for future progress in hepatitis research, enabling scientists to study human disease and vaccines in the ultimate lab animal. In a study to be published in mBio, the online open-access journal of the American Society for Microbiology, scientists describe their search for viruses related to the human hepatitis C virus (HCV) and human pegiviruses (HPgV) in frozen stocks of wild mice. The discovery of several new species of hepaciviruses and pegiviruses that are closely related to human viruses suggests they might be used to study these diseases and potential vaccines in mice, without the need for human volunteers.
About 2% of the population is infected with the hepatitis C virus and 5% is infected with human pegiviruses, but it's been difficult to study new drugs or develop vaccines against these infections because the human strains do not infect animals that can be studied in the lab. Lead author Amit Kapoor of Columbia University says it surprised him to find similar viruses in mice.
"People have been waiting for decades to find something like this. It was shocking for me to see that the viruses are there and there are so many of them," says Kapoor.
Kapoor and his colleagues screened an archive of more than 400 frozen rodents, mostly deer mice, for viruses related to the human hepatitis C virus and human pegiviruses. The search turned up a number of candidates, and they selected two for complete genome sequencing: a rodent hepacivirus (RHV) found in deer mice and a rodent pegivirus (RPgV) found in a white-throated woodrat. Sequencing confirmed that the viruses are very closely related to human strains but they represent several novel species in the Hepacivirus and Pegivirus genera within the family Flaviviridae.
These rodent viruses have genes, proteins, and translational elements that closely mirror those found in human hepaciviruses and pegiviruses, suggesting they have great potential for use in the lab. Animal models of hepatitis would help scientists explore the ways these viruses causes disease and aid in the design of treatments and vaccines. Human pegiviruses, on the other hand, have unknown effects, so studying how they work in rodents could well point the way to what they might do in the human body and why so many people are infected.
Kapoor's lab is now focused on exploring the biology of these viruses. "We are trying to infect deer mice, to study biological properties of these hepatitis C-like viruses," says Kapoor. "And if we find one of these viruses is hepatotrophic [having an attraction to the liver] and causes disease similar to hepatitis C, that would be a big step forward in understanding hepatitis C-induced pathology in humans."
###
mBio is an open access online journal published by the American Society for Microbiology to make microbiology research broadly accessible. The focus of the journal is on rapid publication of cutting-edge research spanning the entire spectrum of microbiology and related fields. It can be found online at http://mbio.asm.org.
Holiday Lectures or Science: Bacteria #39;s Deadly Design
Lecture by C. Erec Stebbins, Associate Professor, The Rockefeller University When it comes to the evolution of life on earth, those who have been here longes...
By: RockefellerUniv
More here:
Holiday Lectures or Science: Bacteria's Deadly Design - Video
You are NOT What You Eat! Functional Paleo Video #2
Did you know that 60% of the American population suffers from at least one system of poor digestion -- gas, bloating, belching, heartburn, constipation, diar...
By: Paleohacks
Read the original here:
You are NOT What You Eat! Functional Paleo Video #2 - Video
6 months post medial closing wedge Distal Femoral Osteotomy
By: hampshireknee
Read the original post:
6 months post medial closing wedge Distal Femoral Osteotomy - Video
AMU SILVER JUBILEE CELEBRATION
for more news plz visit our website http://www.aligarhkhabar.com.
By: Aligarh Khabar
XF PMP was developed in partnership with the Pioneer Valley Life Sciences Institute (PVLSI), a joint venture of Baystate Medical Center and the University of Massachusetts Amherst, with the dual missions of biomedical research and economic development. The technology was exclusively licensed to Seahorse Bioscience by UMass Amherst and Baystate Health, the parent organization of Baystate Medical Center.
XF PMP can be used with the Seahorse XF(e) Extracellular Flux Analyzer, an instrument for measuring cell metabolism, in real-time, in a microplate. The reagent was developed for XF technology in part by Dr. Nagendra Yadava, the John Adams Investigator at PVLSI; and Dr. Alejandro Heuck, Ph.D., an Assistant Professor of Biochemistry and Molecular Biology at UMass Amherst.
"In the development of this potent new tool in biomedical analysis, we see the tremendous potential of collaborations between clinical and academic researchers and ingenuitive companies like Seahorse," said Richard Friedberg, M.D., Ph.D., chair of Pathology and chair of the Intellectual Property Committee at Baystate Health, who represented Baystate in working with Seahorse and UMass to establish the licensing agreement.
XF PMP creates pores in the cell plasma membrane, and delivers a degree of precision and ease-of-use that has not been available to scientists researching cell metabolism. A key element of XF PMP is the ability to assess mitochondrial function in adherent monolayers of permeabilized cells without damaging the mitochondrial membrane. By doing so, XF PMP enables metabolic substrates, compounds, and small proteins that otherwise would not cross the plasma membrane to reach the mitochondria.
"Seahorse's new XF Plasma Membrane Permeabilizer [PMP] enabled us to demonstrate that clinically-relevant concentrations of thiazolidinediones, a class of insulin sensitizers that includes Actos, specifically inhibited the mitochondrial pyruvate carrier, a protein at the hub of cellular metabolism. The simplicity and reliability of XF PMP made it easy to interrogate the mitochondrial function of small clinical samples and genetically modified cells without mitochondrial isolation, experiments that are traditionally difficult or impossible. Our work is providing a new understanding of the mechanism of action of an important class of drugs, and opens a new avenue for the development of drugs to treat diseases including type 2 diabetes, neurodegenerative disease, and heart failure," stated Anne N. Murphy, Ph.D., Associate Professor of Pharmacology at University of California, San Diego.
About Seahorse Bioscience Seahorse Bioscience provides industry-leading analytical instruments, cell-based assay kits, and consumable labware products for biological research and drug discovery. Scientists worldwide use these tools to advance their research in understanding the role of mitochondrial dysfunction in cancer, neuroscience, immunology, obesity, diabetes, ageing, cardiovascular function, and safety toxicity. Seahorse is headquartered in Billerica, Massachusetts; has its manufacturing facilities in Chicopee, Massachusetts; and regional headquarters in Copenhagen and Shanghai. For more information visit: http://www.seahorsebio.com.
About Baystate Medical Center Baystate Medical Center is an academic, research and teaching hospital that serves as the western campus of Tufts University School of Medicine. It is the major referral care center and only Level 1 trauma center for western Massachusetts, and is home to one of New England's busiest emergency rooms. One of Thomson Reuters/Truven Health Analytics' top 50 U.S. hospitals for cardiovascular care and top 100 U.S. hospitals, Baystate Medical Center is also designated a Leapfrog Top Hospital for quality and safety, is a Magnet hospital for nursing excellence, and is a six-time winner of the Beacon Award for Critical Care Excellence. http://www.baystatehealth.org/bmc
About the University of Massachusetts Amherst The University of Massachusetts Amherst, the flagship campus of the UMass system, is one of the nation's top public research universities with 28,000 students studying in the scenic Pioneer Valley of Western Massachusetts. Celebrating its 150th anniversary in 2013, UMass Amherst offers 108 undergraduate degree programs (including six associate degrees) as well as 76 masters and 50 doctoral programs. For more information visit: http://www.umass.edu.
About the Pioneer Valley Life Sciences Institute PVLSI was created in 2002 as a joint venture of Baystate Medical Center and the University of Massachusetts Amherst, with the dual missions of biomedical research and economic development. Drawing on each of the founders as well as its own researchers, the Institute brings together physicians, scientists, and engineers to create interdisciplinary and multidisciplinary teams focused on the molecular mechanisms of disease and the development of new diagnostic and therapeutic tools. For more information visit: http://www.pvlsi.org.
Contact: Naomi Goumillout, 1-978-671-1619, ngoumillout@seahorsebio.com
Link:
Reagent aids scientists in mitochondrial dysfunction analysis.
Age Rejuvenation Centers - The Future of Healthcare | Look and Feel 20 years younger
http://www.Agerejuvenationcenters.com Age Rejuvenation Center "Do you feel sluggish or tired? Are you overweight? Are you living life to the fullest? Hormone Replac...
By: AgeRejuvenationCtrs
Go here to see the original:
Age Rejuvenation Centers - The Future of Healthcare | Look and Feel 20 years younger - Video
Bayer AG ( BAYRY ) recently presented positive results on ATX-101 at the 11th Anti-Aging Medicine World Congress (AMWC) 2013. ATX-101 is being developed for the reduction of unwanted fat deposits under the chin- submental fat (SMF).
Results from a phase IIa study showed that ATX-101 significantly and consistently reduces SMF. The level of SMF reduction was sustained in more than 90% patients who responded to treatment. Moreover, treatment satisfaction was sustained in more than 80% of these patients.
Results from another phase I pharmaco-kinetic study showed that the permanent destruction of fat cells (adipocytolysis) made by ATX-101 did not have any clinically significant impact on the serum lipid levels of the patients in the study. Notably, ATX-101 is the first injectable candidate being evaluated as a non-surgical treatment for SMF reduction in a comprehensive clinical trial setting.
In Feb 2013, Bayer presented positive results from two European phase III studies on ATX-101 at the International Master Course on Aging Skin (IMCAS). Results from the studies showed that ATX-101 reduced SMF more than placebo. ATX-101 demonstrated significant improvement in clinician-reported measurements of SMF, supported by objective caliper measurements of SMF thickness, in comparison to placebo.
Results also revealed that patients were more satisfied with their chin appearance and their treatment with ATX-101 than placebo. The candidate was well tolerated in both the studies.
We note that the studies are part of the ATX-101 clinical development program which is being conducted jointly by Bayer and Kythera Biopharmaceuticals Inc. ( KYTH ) since 2010. As per the 2010 licensing deal between the companies, Bayer acquired rights to ATX-101 in markets outside the US and Canada.
Kythera is eligible to receive tiered double-digit royalties on the sales of the drug made by Bayer outside the US and Canada. Kythera and Bayer have however collaborated to develop ATX-101 in Europe.
In Nov 2012, Kythera had reported positive interim results from a multicenter, open-label, long-term study on ATX-101. The study revealed that the candidate was well tolerated and demonstrated a similar safety profile to that observed in previous studies conducted with the candidate.
We note that Bayer suffered a huge setback last month when the company and its partner Johnson & Johnson ( JNJ ) received a second complete response letter (CRL) from the US Food and Drug Administration (FDA) for their supplemental New Drug Application (sNDA) for Xarelto (2.5 mg twice daily) for the reduction of the risk of secondary cardiovascular events in patients suffering from ACS.
The second CRL for Xarelto is a big disappointment for the company. Bayer carries a Zacks Rank #4 (Sell). The setback regarding Xarelto is primarily responsible for the bearish rank carried by the company. Cytokinetics Inc. ( CYTK ) currently looks better positioned in the pharma space carrying a Zacks Rank #1 (Strong Buy).
See the article here:
Data Presented on Bayer's ATX-101 - Analyst Blog
Health guru Yuri Elkaim is sharing his revolutionary yet simple-to-follow nutrition program through SuperNutritionAcademy.com, and he promises regular folks reliable health results that will change the way they consume and understand food.
Toronto, Canada (PRWEB) April 03, 2013
For Mr. Elkaim, the path to correct understanding was not easy as theres just too much information about health and nutrition these days a lot of them even contradict each other, hence creating great confusion for those who are looking for the most effective ways to lose weight, gain more energy and really improve their overall health. When it comes to working with available information, he says, The solution isnt more information but the right information, and people should learn to be selective of the information they consume as with the food they eat.
Through the well-researched and scientifically-backed bite-sized health and nutrition lessons (developed through 13 years of research and over 1,000 hours of additional research) Mr. Elkaim provides through the Super Nutrition Academy, anyone can become their own health master. At a very affordable fee, they can gain a better understanding of how their body and food interact and thats really what would create a change in their bodies and attitude towards their food choices, preparation and intake.
Many of the worlds most respected health and nutrition professionals laud the lessons and their efficacy. Sean Croxton, founder of Underground Wellness and author of Dark Side of Fat Loss, raves about the program: Yuri (err, Professor) Elkaim has put together an online curriculum loaded with truth bombs. And best of all, this course is structured with everyone in mind. Even I learned a lot while going through the modules! Meanwhile, Jeff Anderson , Founder & Editor of Do This Be Fit Publications says, Hands down, Yuri is my go-to guru when it comes to uncovering the secrets of natural nutrition and achieving an enlightened state of health-consciousness. Ive always prided myself on living a fit lifestyle, but each time I speak with Yuri, I learn something new that allows me to tweak my own personal wellness plan a little bit more and reap the rewards his extensive knowledge has gifted me.
With these reviews, Mr. Elkaim is definitely doing things right and he continues to share his expert knowledge about a wide range of health topics like the dangers of sugar, juicing benefits, common food allergies and so much more. To learn more about the nutrition program that Mr. Elkaim has developed and his take on different health issues, visit http://www.SuperNutritionAcademy.com.
Adam Elkaim Super Nutrition Academy 1-888-529-9541 701 Email Information
Original post:
Newly Developed Nutrition Program Promises Everyday People an Easy and Effective Way to Good Health
Immuno Applications Part IV by Cholene Espinoza
By: CellsActingBadly
Read the rest here:
Immuno Applications Part IV by Cholene Espinoza - Video
Immuno Applications Part V by Cholene Espinoza
By: CellsActingBadly
Here is the original post:
Immuno Applications Part V by Cholene Espinoza - Video
#1 Biochemistry Lecture (Introduction) from Kevin Ahern #39;s BB 350
1. Contact me at kgahern@davincipress.com / Friend me on Facebook (kevin.g.ahern) 2. Download my new free biochemistry book at http://biochem.science.oregons...
By: Kevin Ahern
Go here to see the original:
#1 Biochemistry Lecture (Introduction) from Kevin Ahern's BB 350 - Video
#2 Biochemistry Lecture (Acids/Bases) from Kevin Ahern #39;s BB 350
Contact me at kgahern@davincipress.com / Friend me on Facebook (kevin.g.ahern@facebook.com) Download my new free biochemistry book at http://biochem.science....
By: Kevin Ahern
Read the original:
#2 Biochemistry Lecture (Acids/Bases) from Kevin Ahern's BB 350 - Video